文献速递重症综合管理与镇静镇痛

麻醉科医师术中交接对成人死亡、再入院或术后并发症的影响:HandiCAP随机临床试验

Effect of Intraoperative Handovers of Anesthesia Care on Mortality, Readmission, or Postoperative Complications Among Adults: The HandiCAP Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01
一句话结论在接受长时间大手术的成人中,麻醉科医师术中交接与不交接相比,30天死亡、再入院或严重术后并发症的复合终点无显著差异(30% vs 33%,RD -2.5%,OR 0.89,P=0.27)。

HandiCAP是一项在德国12个中心开展的平行组随机临床试验,纳入美国麻醉医师学会体能状态3或4级、拟行预计至少2小时的大手术住院患者,随机分为麻醉交接组(n=908)和不交接组(n=909)。主要终点为30天全因死亡、再入院或严重术后并发症的复合终点,交接组268/891(30%)vs 不交接组284/881(33%),绝对风险差-2.5%(95%CI -6.8%至1.9%),OR 0.89(95%CI 0.72-1.10),P=0.27。19项预设次要终点均无显著差异。结论提示术中麻醉交接与不交接在主要复合终点上无显著差异。

要点

  • 在1817例美国麻醉医师学会体能状态3或4级、大手术患者中,麻醉交接组30天复合终点(死亡、再入院或严重并发症)发生率为30%(268/891),不交接组为33%(284/881),OR 0.89(95%CI 0.72-1.10),P=0.27。
  • 30天全因死亡率交接组2.1%(19/889)vs 不交接组3.4%(30/873),绝对风险差-1.3%(95%CI -2.8%至0.2%),OR 0.61(95%CI 0.34-1.10),P=0.11。
  • 30天再入院率交接组13%(115/888)vs 不交接组16%(136/872),绝对风险差-2.7%(95%CI -5.9%至0.6%),OR 0.80(95%CI 0.61-1.05),P=0.12。
  • 严重术后并发症交接组22%(195/890)vs 不交接组22%(189/874),绝对风险差0.3%(95%CI -3.6%至4.1%),OR 1.02(95%CI 0.81-1.28),P=0.91。
  • 19项预设次要终点均无显著差异;参与机构均未使用标准化交接方案。

适用人群与场景

  • 美国麻醉医师学会体能状态3或4级、拟行预计至少2小时的大手术住院成人患者,在德国12个中心纳入。

诊断标准与关键阈值

  • 纳入标准:美国麻醉医师学会体能状态3或4级,拟行预计至少2小时的大手术住院手术。

处置流程与药物剂量

  • 干预组(n=908)接受麻醉护理完全交接给另一位临床医师;对照组(n=909)不进行麻醉交接。
  • 参与机构均未使用标准化交接方案。

研究设计与关键结果

  • 平行组随机临床试验,在德国12个中心开展,2019年6月至2021年6月入组,最终随访2021年7月31日;1817例随机,1772例(98%)完成试验;平均年龄66岁(SD 12),男性997例(56%),美国麻醉医师学会体能状态3级1717例(97%)。
  • 麻醉总时间中位数267分钟(IQR 206-351分钟),交接组从麻醉开始至首次交接的中位时间144分钟(IQR 105-213分钟)。
  • 主要复合终点(30天全因死亡、再入院或严重术后并发症):交接组268/891(30%)vs 不交接组284/881(33%),绝对风险差-2.5%(95%CI -6.8%至1.9%),OR 0.89(95%CI 0.72-1.10),P=0.27。
  • 30天全因死亡:交接组19/889(2.1%)vs 不交接组30/873(3.4%),绝对风险差-1.3%(95%CI -2.8%至0.2%),OR 0.61(95%CI 0.34-1.10),P=0.11。
  • 30天再入院:交接组115/888(13%)vs 不交接组136/872(16%),绝对风险差-2.7%(95%CI -5.9%至0.6%),OR 0.80(95%CI 0.61-1.05),P=0.12。
  • 严重术后并发症:交接组195/890(22%)vs 不交接组189/874(22%),绝对风险差0.3%(95%CI -3.6%至4.1%),OR 1.02(95%CI 0.81-1.28),P=0.91。
  • 19项预设次要终点均无显著差异。

证据类型、等级与局限

  • 证据类型:随机临床试验(平行组)。
  • 试验注册:ClinicalTrials.gov Identifier: NCT04016454。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在接受长时间大手术的美国麻醉医师学会体能状态3或4级成人中,麻醉交接与不交接相比,30天死亡、再入院或严重术后并发症的复合终点无显著差异;参与机构均未使用标准化交接方案。

指南或共识出处

  • HandiCAP随机临床试验,ClinicalTrials.gov Identifier: NCT04016454,发表于JAMA。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Intraoperative handovers of anesthesia care are common. Handovers might improve care by reducing physician fatigue, but there is also an inherent risk of losing critical information. Large observational analyses report associations between handover of anesthesia care and adverse events, including higher mortality.

OBJECTIVE: To determine the effect of handovers of anesthesia care on postoperative morbidity and mortality.

DESIGN, SETTING, AND PARTICIPANTS: This was a parallel-group, randomized clinical trial conducted in 12 German centers with patients enrolled between June 2019 and June 2021 (final follow-up, July 31, 2021). Eligible participants had an American Society of Anesthesiologists physical status 3 or 4 and were scheduled for major inpatient surgery expected to last at least 2 hours.

INTERVENTIONS: A total of 1817 participants were randomized to receive either a complete handover to receive anesthesia care by another clinician (n = 908) or no handover of anesthesia care (n = 909). None of the participating institutions used a standardized handover protocol.

MAIN OUTCOMES AND MEASURES: The primary outcome was a 30-day composite of all-cause mortality, hospital readmission, or serious postoperative complications. There were 19 secondary outcomes, including the components of the primary composite, along with intensive care unit and hospital lengths of stay.

RESULTS: Among 1817 randomized patients, 1772 (98%; mean age, 66 [SD, 12] years; 997 men [56%]; and 1717 [97%] with an American Society of Anesthesiologists physical status of 3) completed the trial. The median total duration of anesthesia was 267 minutes (IQR, 206-351 minutes), and the median time from start of anesthesia to first handover was 144 minutes in the handover group (IQR, 105-213 minutes). The composite primary outcome occurred in 268 of 891 patients (30%) in the handover group and in 284 of 881 (33%) in the no handover group (absolute risk difference [RD], -2.5%; 95% CI, -6.8% to 1.9%; odds ratio [OR], 0.89; 95% CI, 0.72 to 1.10; P = .27). Nineteen of 889 patients (2.1%) in the handover group and 30 of 873 (3.4%) in the no handover group experienced all-cause 30-day mortality (absolute RD, -1.3%; 95% CI, -2.8% to 0.2%; OR, 0.61; 95% CI, 0.34 to 1.10; P = .11); 115 of 888 (13%) vs 136 of 872 (16%) were readmitted to the hospital (absolute RD, -2.7%; 95% CI, -5.9% to 0.6%; OR, 0.80; 95% CI, 0.61 to 1.05; P = .12); and 195 of 890 (22%) vs 189 of 874 (22%) experienced serious postoperative complications (absolute RD, 0.3%; 95% CI, -3.6% to 4.1%; odds ratio, 1.02; 95% CI, 0.81 to 1.28; P = .91). None of the 19 prespecified secondary end points differed significantly.

CONCLUSIONS AND RELEVANCE: Among adults undergoing extended surgical procedures, there was no significant difference between the patients randomized to receive handover of anesthesia care from one clinician to another, compared with the no handover group, in the composite primary outcome of mortality, readmission, or serious postoperative complications within 30 days.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04016454.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Meersch M, Weiss R, Küllmar M, et al. Effect of Intraoperative Handovers of Anesthesia Care on Mortality, Readmission, or Postoperative Complications Among Adults: The HandiCAP Randomized Clinical Trial. JAMA. 2022. PMID: 35665794. doi:10.1001/jama.2022.9451

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。